This is a divisional of application Ser. No. 08/706,308 filed Aug. 30, 1996, now U.S. Pat. No. 5,846,948.
The government may own certain rights in this application by virtue of federal funding under grant numbers AI124009 (NIAID) and CA47451 (NCI).
Entry |
---|
Orkin et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 7, 1995.* |
Coglan, New Scientist, Nov. 25, 1995, pp. 14-15.* |
Carter and Roizman, “The Promoter an d Transcriptional Unit of a Novel Herpes Simplex Virus 1 α Gene are Contained in, and Encode a Protein in Frame with, the Open Reading Frame of the α22 Gene,” J Virology, 70(1):172-178, Jan. 1996. |
DeLuca et al., “Isolation and Characterization of Deletion Mutants of Herpes Simplex Virus Type 1 in the Gene Encoding Immediate-Early Regulatory Protein ICP4,” J Virology, 56(2):558-570, Nov. 1985. |
Fu, “The Superfamily of Arginine/Serine-Rich Splicing Factors,” RNA, 1:663-680, 1995. |
Glorioso et al., “Development and Application of Herpes Simplex Virus Vectors for Human Gene Therapy,” Annu rev Microbiol, 49:675-710, 1995. |
Honess and Roizman, “Regulation of Herpes Virus Macromolecular Synthesis. I. Cascade Regulation of the Synthesis of Three Groups of Viral Proteins,” J Virology, 14(1):8-19, Jul. 1974. |
Kanopka et al., “Inhibition by SR Proteins of Splicing of a Regulated Adenovirus Pre-mRNA,” Nature, 381:535-538, Jun. 1996. |
Lagunoff and Roizman, “The Regulation of Synthesis and Protein Product of Open Reading Frame P of the Herpes Simplex Virus 1 Genome,” J Virology, 69(6):3615-3623, Jun. 1995. |
Lagunoff et al., “Phenotypic Properties of Herpes Simplex Virus 1 Containing a Depressed Open Reading Frame P Gene,” J Virology, 70(3):1810-1817, Mar. 1996. |
McNally and McNally, “SR Protein Splicing Factors Interact with the Rous Sarcoma Virus Negative Regulator of Splicing Element,” J Virol, 70(2):1163-1172, Feb. 1996. |
Pettersson et al., “The Structure of Mammalian Small Nuclear Ribonucleoproteins,” J Biological Chemistry, 259(5907-5914, May 1984. |
Ward and Roizman, “Herpes Simplex Genes: The Blueprint of a Successful Human Pathogen,” Trends Genet, 10(8):267-274, Aug. 1994. |
Bruni and Roizman, “Open reading frame P-aherpes simplex virus gene repressed during productive infection encodes a protein that binds a slicing factor and reduces synthesis of viral proteins made from spliced mRNA,” Proc. Natl. Acad. Sci. USA, 93:10423-10427, Sep. 1996. |
International Search Report dated Dec. 19, 1997. (ARCD:241P). |
Lagunoff and Roizman, “Expression of a herpes simplex virus 1 open reading frame antisense to the γ134.5 gene and transcribed by an RNA 3'coterminal with the unspliced latency-associated transcript,” J. Virol., 68(9):6021-6028, Sep. 1994. |
Gura, “Antisense has growing pains,” Science, 270:575-577, 1995. |
Harris et al., TIBSTECH, 11:42-44, 1993. |
Miller et al., Parasitology Today, 10(3):92-97, 1994. |
Rojanasakul, Advanced Drug Delivery Reviews, 18:115-131, 1996. |
Stein et al., “Antisense oligonucleotides as therapeutic agents—is the bullet really magical?” Science, 261:1004-1012, 1993. |
Stull et al., “Some characteristics of metabolism of organochlorine componds in the bovine,” Pharmaceutical Research, 12(4):465-483, 1995. |
Wagner et al., “Gene inhibition using antisense oligodeoxynucleotides,” Nature 372:333-335, 1994. |
Weiss et al., Science News, 139:108-109, 1991. |
Wu Pong, Pharmaceutical Technology, 18:102-114, 1994. |